Suggested remit: To appraise the clinical and cost effectiveness of setmelanotide within its marketing authorisation for treating obesity and hyperphagia caused by Bardet-Biedl Syndrome (BBS).
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Awaiting decision
|
Process |
STA Standard
|
ID number |
3947
|
Project Team
Project lead |
Celia Mayers |
Email enquiries
External Assessment Group |
Bristol Technology Assessment Group, University of Bristol |
Stakeholders
Companies sponsors |
Rhythm Pharmaceuticals (Setmelanotide) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Bardet-Biedl Syndrome UK |
Professional groups |
British Obesity & Metabolic Surgery Society |
|
Royal College of Physicians |
Comparator companies |
Novo Nordisk (semaglutide) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare Products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
|
Welsh Government |
Relevant research groups |
National Institute for Health Research |
Date
|
Update
|
22 February 2024 - 14 March 2024
|
Draft guidance: 2 |
07 December 2023
|
Committee meeting: 3 |
14 September 2023
|
Committee meeting: 2 |
03 August 2023 - 24 August 2023
|
Draft guidance |
13 July 2023
|
Committee meeting |
15 February 2023
|
In progress. In progress. |
09 November 2022
|
Invitation to participate |
30 March 2022
|
The topic was discussed at the Topic Selection Oversight Panel (TSOP) in March 2022. The panel concluded that the topic was suitable for a Highly Specialised Technologies (HST) evaluation. |
30 March 2022
|
Topic selection |
15 December 2021 (14:00)
|
Scoping workshop |
03 November 2021 - 01 December 2021
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
23 September 2021
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual